The European Commission has given its blessing for the proposed £46-billion acquisition of Shire by Takeda, paving the way for the deal’s completion.
News
Psychological therapy recovery rate surpasses 50% for the first time
More than half of patients who finished psychological therapy recovered in 2017-18, marking the first time the recovery rate has passed 50%.
European Commission approves Lilly’s Emgality for migraine
Eli Lilly has confirmed that Emgality, a once-monthly monoclonal antibody injection, has been approved by the European Commission for preventive treatment of migraine in adults who have at least four migraine days per month.
First Rare Disease Collaborative Network for refractory coeliac disease
Refractory coeliac disease, a deadly form of the autoimmune condition coeliac disease, has received its first dedicated support from NHS England, with the setting up of a Rare Disease Collaborative Network (RDCN) to accelerate research and treatment into this life threatening condition.
Mirati joins CR UK’s Stratified Medicine Programme
Mirati Therapeutics has joined Cancer Research UK’s Stratified Medicine Programme, bringing new investigational treatment options to eligible patients with advanced lung cancer.
GSK files Nucala for wider paediatric use
GlaxoSmithKline is seeking to expand the use of its biologic Nucala in the US to include children aged six to 11 years with severe eosinophilic asthma.
Public show ‘overwhelming’ support for reducing sugar, calories in food
A survey commissioned by Public Health England (PHE) has found that around nine in ten people support the government working with the food industry to make food healthier.
Merck, Pfizer’s Bavencio misses ovarian cancer trial endpoints
A late-stage study testing Merck KGaA and Pfizer’s PD-L1 antibody Bavencio has failed to meet its primary endpoints in patients with certain forms of ovarian cancer.
Cardiff Uni and Takeda team up for new drug discovery collaboration
Cardiff University has formed a drug discovery collaboration with Takeda to identify new approaches for treating schizophrenia and other psychiatric disorders.
FDA expands scope of Novartis’ Promacta
US regulators have expanded the scope of Novartis’ Promacta to include earlier use of the drug to treat adults and paediatric patients with severe aplastic anaemia (SAA) in combination with standard immunosuppressive therapy (IST).
Setback for AZ’ Imfinzi lung cancer combination
AstraZeneca’s Imfinzi has failed to show a significant benefit over standard of care (SoC) chemotherapy on overall survival in certain patients with lung cancer.
NICE green light for Keytruda in melanoma setting
NICE has given a green light for use of MSD’s Keytruda on the NHS to treat some patients with melanoma, with funding to come from the Cancer Drugs Fund.
CHMP backs four medicines for approval
Four medicines have taken a giant leap closer to approval having won the backing of the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).
The PharmaTimes Marketer, Communications Team of the Year & Sales Awards 2018 – winners announced!
The annual PharmaTimes Marketer of the Year and Communications Team of the Year awards ceremonies took place last night at the Tower Hotel London, with a special addition for this year – the PharmaTimes Sales Awards.
BHA, ABPI welcome UK’s EU withdrawal agreement
The Brexit Health Alliance (BHA) has welcomed the agreement on the terms of the UK’s withdrawal from the European Union (EU).
